KR937000438A - 3-인돌릴 티오아세테이트 유도체 - Google Patents

3-인돌릴 티오아세테이트 유도체

Info

Publication number
KR937000438A
KR937000438A KR1019920702634A KR920702634A KR937000438A KR 937000438 A KR937000438 A KR 937000438A KR 1019920702634 A KR1019920702634 A KR 1019920702634A KR 920702634 A KR920702634 A KR 920702634A KR 937000438 A KR937000438 A KR 937000438A
Authority
KR
South Korea
Prior art keywords
compound according
administering
compound
patient
alkyl
Prior art date
Application number
KR1019920702634A
Other languages
English (en)
Other versions
KR0178281B1 (ko
Inventor
지. 살리투로 프란세스코
엠. 바론 브루스
Original Assignee
스티븐 엘. 네스비트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 엘. 네스비트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 스티븐 엘. 네스비트
Publication of KR937000438A publication Critical patent/KR937000438A/ko
Application granted granted Critical
Publication of KR0178281B1 publication Critical patent/KR0178281B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Lubricants (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음.

Description

3-인돌릴 티오아세테이트 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 부가염.
    상기식에서, Z는 H, C1-4알킬, 페닐, 치환된 페닐 또는 페닐 환이 임의로 치환될 수 있는 알킬페닐 치환체이고; X는 S,SO 또는 SO2이고; m은 1내지 4의 정수이고; R은 수소, 할로겐, C1-4알킬, C1-4알콕시, CF3,OCF3,OH,NO2또는 CN이고; R1및 R2는 각각 독립적으로 -OH, -OR3,-NR4R5,-COH2OR3또는 -0-(CH2)n- NR6R7(여기서, n은 1내지 4의 정수이고, R3은 C1-4알킬, 페닐, 치환된 페닐 또는 페닐 환이 임의로 치환될 수 있는 알킬페닐 치환체이고; R4및 R5는 각각 독립적으로 수소 또는 C1-4알킬이고; R6및 R7은 각각 독립적으로 수소 또는 C1-4알킬이거나, R6및 R7은 인접한 질소원자와 함께 피페리디노, 모르폴리노 또는 피롤리디노 그룹을 형성한다)이다.
  2. 제1항에 있어서, R이 4,6-디클로로 치환체인 화합물.
  3. 제1항에 있어서, X가 황인 화합물.
  4. 제1항에 있어서, X가 SO인 화합물.
  5. 제1항에 있어서, X가 SO2인 화합물.
  6. 제1항에 따른 화합물의 길항적 양을 이를 필요로 하는 환자에게 투여함을 포함하여 NMDA 수용체 착체에 대한 흥분성 아미노산 효과를 길항하는 방법.
  7. 제1항에 따른 화합물의 간질 치료양을 이를 필요로 하는 환자에게 투여함을 포함하여 간질을 치료하는 방법.
  8. 제1항에 따른 화합물의 유효량을 이를 필요로 하는 환자에게 투여함을 포함하여 신경변성 질환을 치료하는 방법.
  9. 제1항에 따른 화합물의 유효량을 이를 필요로 하는 환자에게 투여함을 포함하여 뇌조직에 대한 허혈성/저산소성/저혈당성 손상을 방지하는 방법.
  10. 제1항에 따른 화합물의 불안 해소량을 투여함을 포함하여 불안을 치료하는 방법.
  11. 제1항에 따른 화합물의 진통 해소량을 이를 필요로 하는 환자에게 투여함을 포함하여 진통효과를 생성하는 방법.
  12. 제1항에 따른 화합물을 약제학적으로 허용되는 담체와 혼합하여 포함하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920702634A 1990-04-25 1991-03-28 3-인돌릴 티오아세테이트 유도체 및 이를 함유하는 약제학적 조성물 KR0178281B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/514,074 US5051442A (en) 1990-04-25 1990-04-25 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
US07/514074 1990-04-25
US7/514,074 1990-04-25
PCT/US1991/002179 WO1991016307A1 (en) 1990-04-25 1991-03-28 3-indolyl thioacetate derivatives

Publications (2)

Publication Number Publication Date
KR937000438A true KR937000438A (ko) 1993-03-15
KR0178281B1 KR0178281B1 (ko) 1999-03-20

Family

ID=24045696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702634A KR0178281B1 (ko) 1990-04-25 1991-03-28 3-인돌릴 티오아세테이트 유도체 및 이를 함유하는 약제학적 조성물

Country Status (14)

Country Link
US (1) US5051442A (ko)
EP (1) EP0526478B1 (ko)
JP (1) JP3006881B2 (ko)
KR (1) KR0178281B1 (ko)
AT (1) ATE119882T1 (ko)
AU (1) AU646251B2 (ko)
CA (1) CA2081330C (ko)
DE (1) DE69108234T2 (ko)
DK (1) DK0526478T3 (ko)
ES (1) ES2072607T3 (ko)
FI (1) FI98454C (ko)
HU (1) HU213205B (ko)
NO (1) NO178857C (ko)
WO (1) WO1991016307A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
US5801168A (en) * 1994-06-09 1998-09-01 Zeneca Limited Substituted nitrogen heterocycles
ATE206701T1 (de) * 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (en) 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
JP6025853B2 (ja) 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
IL84796A (en) * 1986-12-17 1992-03-29 Merck Frosst Canada Inc Substituted n-benzyl-indoles and pharmaceutical compositions containing them
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物

Also Published As

Publication number Publication date
HUT64744A (en) 1994-02-28
WO1991016307A1 (en) 1991-10-31
KR0178281B1 (ko) 1999-03-20
ATE119882T1 (de) 1995-04-15
DK0526478T3 (da) 1995-05-29
DE69108234T2 (de) 1995-08-24
NO924126D0 (no) 1992-10-23
JP3006881B2 (ja) 2000-02-07
US5051442A (en) 1991-09-24
JPH07500567A (ja) 1995-01-19
FI924642A0 (fi) 1992-10-14
DE69108234D1 (en) 1995-04-20
FI924642A (fi) 1992-10-14
AU646251B2 (en) 1994-02-17
NO178857C (no) 1996-06-19
NO178857B (no) 1996-03-11
ES2072607T3 (es) 1995-07-16
CA2081330A1 (en) 1991-10-26
HU213205B (en) 1997-03-28
FI98454C (fi) 1997-06-25
FI98454B (fi) 1997-03-14
AU7650091A (en) 1991-11-11
NO924126L (no) 1992-10-23
EP0526478B1 (en) 1995-03-15
CA2081330C (en) 2002-02-05
EP0526478A1 (en) 1993-02-10
HU9203336D0 (en) 1993-01-28

Similar Documents

Publication Publication Date Title
KR900015729A (ko) 흥분성 아미노산 길항제
KR920009796A (ko) 3-아미도인돌릴 유도체
KR937000438A (ko) 3-인돌릴 티오아세테이트 유도체
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
RU2002120515A (ru) Гетероциклические соединения, содержащие сульфонамидные группы
NO931317D0 (no) Et terapeutisk middel for parkinson's sykdom
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR900018112A (ko) 흥분성 아미노산 길항제
KR950010891A (ko) 내성 종양을 치료하는 방법
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
ATE156119T1 (de) 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR920016418A (ko) Nmda 길항제
DE69117879D1 (de) Arzneimittel für die Verhütung und Behandlung von Krankheiten der Kreislauforgane enthaltend Spiro-3-heteroazolidin-Verbindungen
RU95104890A (ru) Новые стероиды, содержащие в положении 20 аминозамещенную цепь, метод и промежуточные продукты подготовки данного метода, их применение в качестве медикаментов и включающие их фармацевтические соединения
KR930703257A (ko) 엔엠디에이(nmda) 길항제
KR950702522A (ko) 약리학적으로 활성인 α-[t-아미노메틸]벤젠메탄올 유도체(PHARMACOLOGICALLY ACTIVE α-[TERTIARY-AMINOMETHYL]-BENENEMETHANOL DERIATIVES)
KR920019767A (ko) 티아졸 유도체
KR950704322A (ko) 스피로푸라논 유도체 및 그의 신경변성 질환 치료 용도(Spirofuranone Derivatives and Their Use in the Treatment of Neurodegenerative Disorders)
KR930019683A (ko) 사이클릭 아미노메틸렌 비스포스포네이트 유도체
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
KR940005541A (ko) 치환된 벤조에이트 유도체
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021112

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee